SCHEMBL6611976

SCHEMBL6611976

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccsc1-c1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.49
HSD11B1 P28845 7/20 0.48
EDNRB P24530 2/20 0.46
EDNRA P25101 2/20 0.46
POLB P06746 1/20 0.43
CASP6 P55212 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CCR4 P51679 1/20 0.41
PTGES2 Q9H7Z7 3/20 0.41
BRD4 O60885 1/20 0.41
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
CCR2 P41597 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6613713 0.88 HSD11B1 (0.52) SLC40A1HSD11B1EDNRBEDNRACCR4
SCHEMBL6610399 0.87 SLC40A1 (0.51) SLC40A1HSD11B1EDNRBEDNRACCR4
SCHEMBL6610797 0.83 MCL1 (0.47) SLC40A1HSD11B1EDNRBEDNRAPOLB
SCHEMBL6613196 0.82 SLC40A1 (0.46) SLC40A1HSD11B1EDNRBEDNRACCR4
SCHEMBL6614439 0.81 PTGES2 (0.45) SLC40A1POLBCASP6CTDSP1TDP1
SCHEMBL6610699 0.80 SLC40A1 (0.49) SLC40A1HSD11B1EDNRBEDNRAPOLB
SCHEMBL7594250 0.79 SLC40A1 (0.66) SLC40A1HSD11B1EDNRBEDNRAPOLB
SCHEMBL6616015 0.79 SLC40A1 (0.53) SLC40A1HSD11B1EDNRBEDNRAPOLB
SCHEMBL6611897 0.78 ACLY (0.44) SLC40A1HSD11B1EDNRBEDNRACCR4
SCHEMBL6625264 0.78 SLC40A1 (0.49) SLC40A1HSD11B1EDNRBEDNRACCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 SLC40A1 2287/4885HSD11B1 1/4885EDNRB 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.